Crofelemer Shows Promise in Managing Cancer Therapy-Related Diarrhea in Breast Cancer Patients

Jaguar Health, Inc. has announced that crofelemer, a drug being evaluated for cancer therapy-related diarrhea (CTD), has shown significant results in breast cancer patients. These findings, from the OnTarget trial, will be presented at the San Antonio Breast Cancer Symposium (SABCS) on December 11, 2024. This phase 3 trial focused on adult breast cancer patients receiving targeted therapy, with crofelemer demonstrating noteworthy prophylactic benefits.

A second abstract based on the study's placebo arm has also been accepted for presentation. Jaguar aims to use the study results to engage with the U.S. Food and Drug Administration, hoping to expedite crofelemer's availability to breast cancer patients. The company's ongoing analyses could lead to further scholarly discussions. SABCS, a major cancer research event, anticipates over 10,000 attendees.